Trials / Active Not Recruiting
Active Not RecruitingNCT06895343
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses of ABBV-701 in Healthy Adult Western and Asian Subjects
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single ascending doses of ABBV-701 in healthy adult western and Asian participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-701 | Subcutaneous |
| DRUG | Placebo | Subcutaneous |
| DRUG | ABBV-701 | IV Infusion |
| DRUG | Placebo | IV infusion |
Timeline
- Start date
- 2025-04-03
- Primary completion
- 2026-11-01
- Completion
- 2026-11-01
- First posted
- 2025-03-26
- Last updated
- 2026-03-02
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06895343. Inclusion in this directory is not an endorsement.